Sakthivel Muthu | Cancer biology | Best Researcher Award

Dr. Sakthivel Muthu | Cancer biology | Best Researcher Award 

Assistant Professor, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Chennai-602105, Tamil Nadu, India.

Dr. Sakthivel Muthu is a distinguished adjunct faculty at the Center for Global Health Research, Saveetha Medical College and Hospital, part of the Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India. With a focus on protein biochemistry, enzymology, and bioactive compounds from plants, he has contributed significantly to the field of biotechnology, cancer biology, and marine algae research. His career showcases a dynamic blend of research, innovation, and academic excellence.

Profile

Scopus

Google Scholar

ORCiD

Education

Dr. Muthu completed his Ph.D. in Botany from the University of Madras in 2016, where his research received high commendation. He earned his M.Phil. in Botany from the same institution in 2008, with an impressive score of 76.39%. Prior to that, he completed his M.Sc. in Botany from Madurai Kamaraj University in 2007 and his B.Sc. in Botany in 2005. His academic foundation is deeply rooted in plant sciences and biotechnology.

Experience

Dr. Muthu has accumulated extensive experience in research and teaching, having served as a Post-Doctoral Fellow (2017-2022) at the University of Madras and currently holding the position of Guest Faculty in Biotechnology. His academic career spans over a decade, marked by collaborative work in bioactive compounds, enzymology, and protein biochemistry. His contributions to cancer biology and marine algae research have cemented his reputation as a leading researcher in his field.

Research Interests

Dr. Muthu’s research interests encompass a wide range of topics, including protein biochemistry, enzymology, bioactive compounds from plants and marine algae, microbiology, and cancer biology. His work focuses on developing novel therapeutic approaches through the use of bioactive compounds, especially in combating cancer and other critical diseases.

Awards and Fellowships

Over the course of his academic journey, Dr. Muthu has received several prestigious awards. Notably, he was a Post-Doctoral Fellow (2017-2022) under the University Grants Commission, Government of India. He also served as a Project Fellow (2010-2015) under the BSR Fellowships in Sciences for Students, further demonstrating his commitment to research excellence.

Publications

Dr. Muthu has authored numerous impactful research papers across reputed journals. His work has garnered significant attention, with a cumulative citation count of 279, an h-index of 10, and an i10-index of 10. Some of his notable publications include:

  • Encapsulation of Phloroglucinol from Rosenvingea intricata Macroalgae with Zinc Oxide Nanoparticles against A549 Lung Cancer Cells
    • Published in Pharmaceutics (2024).
    • Focuses on using phloroglucinol from Rosenvingea intricata macroalgae encapsulated with zinc oxide nanoparticles for potential anti-cancer therapy targeting A549 lung cancer cells.
    • Cited by 4.
  • Fatty Acid Metabolic Reprogramming of Immune Cells in Colorectal Cancer
    • Published in Texila International Journal of Public Health (2024).
    • Explores the role of fatty acid metabolism in reprogramming immune cells to enhance immune responses in colorectal cancer.
    • Cited by 5.
  • Anthocyanin-rich Foods: Insights into Extraction, Medicinal Potential, and Sustainable Applications
    • Published in Journal of Agriculture and Food Research (2024).
    • Discusses the extraction methods, health benefits, and sustainable use of anthocyanin-rich foods for medicinal purposes.
    • Cited by 7.
  • Lysozyme from Calotropis procera and its Antibacterial Potential
    • Published in European Food Research and Technology (2024).
    • Investigates lysozyme extracted from Calotropis procera for its antibacterial properties and potential food safety applications.
    • Cited by 10.
  • Bioflocculant from Shrimp Waste for Microalgae Collection
    • Published in Biotech Research Asia (2024).
    • Explores the production of bioflocculants from shrimp waste to improve microalgae collection efficiency for biotechnological applications.
    • Citation count not specified.

Conclusion

Dr. Sakthivel Muthu is a strong contender for the Best Researcher Award based on his wide-ranging research expertise, significant publication record, and noteworthy citation metrics. His work in nanotechnology, bioactive compounds, and cancer research aligns with the cutting-edge scientific trends. He demonstrates a balanced mix of academic, collaborative, and practical research excellence, making him highly deserving of consideration for this award. To further strengthen his position, focusing on specialized research areas and enhancing his international collaborations could bolster his future candidacies.

 

Jiuda Zhao | Oncology – Breast Cancer | Best Researcher Award

Prof. Jiuda Zhao | Oncology – Breast Cancer | Best Researcher Award

Chief Physician at Qinghai University Affiliated Hospital, China.

Jiuda Zhao is a Professor and Chief Physician at the Breast Disease Diagnosis and Treatment Center of the Affiliated Hospital of Qinghai University. With over 20 years of experience, he specializes in the diagnosis and treatment of breast cancer. He has been recognized as a high-end innovative talent and has contributed extensively to the field of oncology, focusing on advancing treatment methods for breast cancer.

Profile

Scopus

Education 

Jiuda Zhao completed his medical education and specialized training in oncology, focusing on breast cancer treatment. His academic journey is further complemented by his supervisory role, where he mentors doctoral students, contributing to the next generation of medical professionals in oncology.

Experience 

Jiuda Zhao has over two decades of clinical experience, particularly in the treatment of breast cancer. His work emphasizes diagnosis, innovative therapies such as immunotherapy and targeted treatments, and he is actively involved in multi-disciplinary approaches (MDT) for breast cancer care. He also contributes to the academic community by serving in various national oncology committees.

Research Interests 

Jiuda Zhao’s research is centered on the diagnosis and treatment of breast cancer, especially in high-altitude regions. His focus extends to endocrine therapy, targeted therapy, and immunotherapy, aiming to enhance treatment outcomes for patients. He is also involved in cross-disciplinary areas such as oncology cardiology and oncology genetics, promoting comprehensive cancer care.

Awards 

Jiuda Zhao has been honored multiple times for his contributions to oncology, including the prestigious Qinghai Provincial Science and Technology Progress Award in 2022. His commitment to cancer prevention and treatment has also earned him recognition as a high-level talent in Qinghai Province.

Publications 

1. Effect of Adding Electroacupuncture to Standard Triple Antiemetic Therapy on Chemotherapy-Induced Nausea and Vomiting: A Randomized Controlled Clinical Trial

  • Journal: Journal of Clinical Oncology
  • Published: September 6, 2024
  • DOI: 10.1200/JCO.24.00099
  • Authors: Shen G, Ren D, Zhao F, Wang M, Liu Z, Feng X, He Y, Liu X, Ling X, Zhao Y, Song F, Ma J, Li E, She T, Liu Z, Li Z, Huang S, Chen Y, Yang J, Li X, Duan L, Da M, Zheng Y, Li Y, Zhao J
  • Summary: This paper investigates the effectiveness of electroacupuncture in reducing chemotherapy-induced nausea and vomiting when added to the standard triple antiemetic therapy. The study is a randomized controlled trial, offering new insights into improving quality of life for chemotherapy patients.

2. Anlotinib: A Novel Multi-Targeting Tyrosine Kinase Inhibitor in Clinical Development

  • Journal: Journal of Hematology & Oncology
  • Published: September 19, 2018
  • DOI: 10.1186/s13045-018-0664-7
  • Authors: Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, Zhao F, Ahmad R, Zhao J
  • Cited by: 462
  • Summary: This paper focuses on Anlotinib, a novel multi-targeting tyrosine kinase inhibitor used in cancer treatment. The research explores its efficacy in various cancer types, emphasizing its clinical potential as a therapeutic agent.

3. Incidence of Antibody-Drug Conjugates-Related Pneumonitis in Patients with Solid Tumors: A Systematic Review and Meta-Analysis

  • Journal: Critical Reviews in Oncology/Hematology
  • Published: April 2023
  • DOI: 10.1016/j.critrevonc.2023.103960
  • Authors: Zhu Z, Shen G, Li J, Qiu T, Fang Q, Zheng Y, Xin Y, Liu Z, Zhao F, Ren D, Zhao J
  • Summary: This meta-analysis assesses the incidence of pneumonitis caused by antibody-drug conjugates in solid tumor treatments. The study offers critical data for managing this rare but serious side effect in cancer therapy.

4. The Emerging Role of Hypoxia-Inducible Factor-2 Involved in Chemo/Radioresistance in Solid Tumors

  • Journal: Cancer Treatment Reviews
  • Published: July 2015
  • DOI: 10.1016/j.ctrv.2015.05.004
  • Authors: Zhao J, Du F, Luo Y, Shen G, Zheng F, Xu B
  • Summary: This paper discusses the role of Hypoxia-Inducible Factor-2 (HIF-2) in contributing to chemotherapy and radiotherapy resistance in solid tumors. It highlights new strategies for overcoming treatment resistance.

5. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis

Conclusion

Jiuda Zhao is a highly deserving candidate for the Best Researcher Award. His significant contributions to breast cancer research, particularly in underserved high-altitude regions, demonstrate his expertise, leadership, and dedication to advancing medical science. His innovations, academic influence, and research outputs place him in a strong position for the award. Addressing areas like industry collaboration and international partnerships could further elevate his profile on a global scale.